KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
20M of 20M shares
Institutional holders
132
15 new, 30 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
6 buys · 12 sales
Net sold $447.18K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 5,389,264 | 13.27% | 13D (active) amendment | Aug 21, 2025 |
| Pontifax Management 4 GP (2015) Ltd. | 4,787,331 | 11.80% | 13D (active) amendment | Apr 17, 2025 |
| ExodusPoint Capital Partners GP, LLC | 1,907,899 | 6.30% | 13G (passive) | Nov 10, 2025 |
| BlackRock, Inc. | 1,671,343 | 8.40% | 13G (passive) amendment | Jun 30, 2026 |
| Daniel Mack | 1,360,419 | 6.90% | 13G (passive) | Mar 31, 2026 |
| BlackRock Portfolio Management LLC | 1,122,874 | 5.70% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KROS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,820,838 | 14.23% | $30.18M | +1,460,419 | 0.50% |
| BlackRock, Inc. | 2,794,217 | 14.09% | $29.90M | +382,424 | 0.00% |
| Aqr Capital Management LLC | 967,859 | 4.88% | $10.36M | +561,296 | 0.00% |
| Vanguard Capital Management LLC | 833,596 | 4.20% | $8.92M | +2,175 | 0.00% |
| Orbimed Advisors LLC | 759,155 | 3.83% | $8.12M | – | 0.15% |
| Federated Hermes, Inc. | 700,427 | 3.53% | $7.49M | +11,198 | 0.01% |
| Vanguard Portfolio Management LLC | 652,635 | 3.29% | $6.98M | −29,408 | 0.00% |
| Mackenzie Financial Corp | 628,438 | 3.17% | $6.72M | +475,988 | 0.01% |
| Madison Avenue Partners, LP | 626,583 | 3.16% | $6.70M | – | 0.29% |
| Qube Research & Technologies Ltd | 608,837 | 3.07% | $6.51M | −116,089 | 0.01% |
| Jacobs Levy Equity Management, Inc | 605,445 | 3.05% | $6.48M | −100,626 | 0.02% |
| State Street Corp | 541,193 | 2.73% | $5.79M | −20,537 | 0.00% |
| Geode Capital Management, LLC | 510,841 | 2.58% | $5.47M | −170,619 | 0.00% |
| Dimensional Fund Advisors LP | 460,541 | 2.32% | $4.93M | +139,181 | 0.00% |
| Citadel Advisors LLC | 396,098 | 2.00% | $4.24M | −10,568 | 0.00% |
| Renaissance Technologies LLC | 359,086 | 1.81% | $3.84M | −94,396 | 0.01% |
| D. E. Shaw & Co., Inc. | 267,460 | 1.35% | $2.86M | −242,148 | 0.00% |
| Bridgeway Capital Management, LLC | 265,017 | 1.34% | $2.84M | +70,000 | 0.05% |
| Nuveen, LLC | 247,756 | 1.25% | $2.65M | −14,319 | 0.00% |
| ADAR1 Capital Management, LLC | 246,818 | 1.24% | $2.64M | +149,500 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 132 | 20M | 100.0% | 15 / 47 | 50 / 30 | 4M | 3M |
| Q1 2026 | 151 | 19M | 93.8% | 27 / 48 | 55 / 40 | 5M | 5M |
| Q4 2025 | 166 | 20M | 100.0% | 41 / 40 | 72 / 26 | 5M | 21M |
| Q3 2025 | 155 | 35M | 100.0% | 29 / 55 | 41 / 13 | 4M | 4M |
| Q2 2025 | 139 | 36M | 100.0% | 27 / 59 | 34 / 43 | 12M | 13M |
| Q1 2025 | 156 | 37M | 100.0% | 49 / 48 | 41 / 50 | 20M | 20M |
| Q4 2024 | 161 | 37M | 100.0% | 38 / 74 | 30 / 40 | 9M | 7M |
| Q3 2024 | 164 | 35M | 100.0% | 28 / 67 | 46 / 15 | 8M | 3M |
| Q2 2024 | 152 | 32M | 100.0% | 23 / 63 | 41 / 17 | 4M | 4M |
| Q1 2024 | 147 | 32M | 100.0% | 37 / 57 | 40 / 10 | 9M | 4M |
| Q4 2023 | 121 | 27M | 100.0% | 27 / 44 | 31 / 12 | 7M | 3M |
| Q3 2023 | 107 | 23M | 100.0% | 4 / 49 | 29 / 20 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KROS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 595,316 | 3.00% | $6.37M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 503,875 | 2.54% | $5.39M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 382,340 | 1.93% | $3.85M | 0.17% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 258,657 | 1.30% | $2.77M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 220,854 | 1.11% | $2.36M | 0.00% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 220,445 | 1.11% | $2.48M | 0.05% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 200,266 | 1.01% | $2.02M | 0.01% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 190,040 | 0.96% | $1.91M | 0.05% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 174,545 | 0.88% | $1.87M | 0.01% | Jun 30, 2026 |
| Vanguard Explorer Fund | 171,150 | 0.86% | $1.72M | 0.01% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 149,903 | 0.76% | $1.69M | 0.01% | May 31, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 149,300 | 0.75% | $1.60M | 0.01% | Jun 30, 2026 |
| Old Westbury Small & Mid Cap Strategies Fund | 143,853 | 0.73% | $1.45M | 0.02% | Jul 31, 2026 |
| U.S. Small Cap Value Portfolio | 142,035 | 0.72% | $1.43M | 0.01% | Jul 31, 2026 |
| iShares Biotechnology ETF | 128,504 | 0.65% | $1.37M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER, Director | 440,708 | 2.22% | Apr 6, 2026 |
| Lorena Raquel Lerner | Chief Scientific Officer | 27,559 | 0.14% | Aug 20, 2026 |
| Annita Tanini | Corp. Controller & VP, Finance | 45,144 | 0.23% | Aug 20, 2026 |
| Esther Cho | Chief Legal Officer | 35,770 | 0.18% | Aug 20, 2026 |
| Keith Regnante | CHIEF FINANCIAL OFFICER | 39,261 | 0.20% | Feb 26, 2026 |
| Yung H. Chyung | Chief Medical Officer | 44,000 | 0.22% | Feb 19, 2025 |
| Christopher Rovaldi | Chief Operating Officer | 60,000 | 0.30% | Feb 19, 2025 |
| Charles W. Newton | Director | 12,114 | 0.06% | Aug 20, 2026 |
| Jean Jacques Bienaime | Director | 19,592 | 0.10% | Aug 19, 2026 |
| Anne Prener | Director | 13,786 | 0.07% | Jul 6, 2026 |
| Nima Farzan | Director | 9,767 | 0.05% | Jun 8, 2026 |
| Julius Knowles | Director | 161,005 | 0.81% | Jun 8, 2026 |
| Mary Ann Gray | Director | 12,392 | 0.06% | Jun 5, 2026 |
| Alpna Seth | Director | 12,392 | 0.06% | Jun 5, 2026 |
| Carl L. Gordon | Director | 764,405 | 3.86% | Dec 18, 2025 |
| Genesis GP LLC OrbiMed | Director | 45,057 | 0.23% | Dec 18, 2025 |
| Capital GP VII LLC OrbiMed | Director | 148,922 | 0.75% | Dec 18, 2025 |
| Advisors Llc Orbimed | Director | – | – | Dec 18, 2025 |
| Ran Nussbaum | Director, 10% owner | 160,512 | 0.81% | Oct 17, 2025 |
| Tomer Kariv | Director, 10% owner | 160,512 | 0.81% | Oct 17, 2025 |
| (Cayman) IV L.P. Pontifax | 10% owner | – | – | Oct 17, 2025 |
| Pontifax (Israel) IV, L.P. | 10% owner | 1,122,768 | 5.66% | Oct 17, 2025 |
| (China) IV L.P. Pontifax | 10% owner | 10,500 | 0.05% | Oct 17, 2025 |
| Late Stage GP Ltd. Pontifax | 10% owner | 1,121,045 | 5.65% | Oct 17, 2025 |
| Late Stage Fund L.P. Pontifax | 10% owner | 2,288,151 | 11.54% | Oct 17, 2025 |
| Management 4 G.P. (2015) Ltd. Pontifax | 10% owner | – | – | Oct 17, 2025 |
| ADAR1 Capital Management GP, LLC | 10% owner | – | – | Oct 15, 2025 |
| Daniel Schneeberger | 10% owner | 0 | – | Oct 15, 2025 |
| ADAR1 Capital Management, LLC | 10% owner | – | – | Oct 15, 2025 |
| ADAR1 Partners, LP | 10% owner | 5,390,964 | 27.19% | Oct 15, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Charles W. Newton Director | Aug 18, 2026 | Sale(10b5-1 plan) | −551 | $10.30 | $5.68K | 12,114 |
| Annita Tanini Corp. Controller & VP, Finance | Aug 18, 2026 | Sale | −1,224 | $10.29 | $12.59K | 45,144 |
| Esther Cho Chief Legal Officer | Aug 18, 2026 | Sale | −4,485 | $10.29 | $46.15K | 35,770 |
| Lorena Raquel Lerner Chief Scientific Officer | Aug 18, 2026 | Sale | −3,568 | $10.29 | $36.71K | 27,559 |
| Jean Jacques Bienaime Director | Aug 17, 2026 | Buy | +1,000 | $10.27 | $10.27K | 19,592 |
| Jean Jacques Bienaime Director | Jul 15, 2026 | Buy | +1,000 | $10.61 | $10.61K | 18,592 |
| Anne Prener Director | Jul 1, 2026 | Award | +13,786 | – | – | 13,786 |
| Jean Jacques Bienaime Director | Jun 15, 2026 | Buy | +1,000 | $10.19 | $10.19K | 17,592 |
| Charles W. Newton Director | Jun 11, 2026 | Sale(10b5-1 plan) | −550 | $10.04 | $5.52K | 12,665 |
| Nima Farzan Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.73 | $28.17K | 9,767 |
| Julius Knowles Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.73 | $28.17K | 10,958 |
| Alpna Seth Director | Jun 4, 2026 | Sale(10b5-1 plan) | −2,625 | $10.72 | $28.14K | 9,767 |
| Julius Knowles Director | Jun 3, 2026 | Award | +7,142 | – | – | 13,583 |
| Nima Farzan Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Mary Ann Gray Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Jean Jacques Bienaime Director | Jun 3, 2026 | Award | +7,142 | – | – | 16,592 |
| Alpna Seth Director | Jun 3, 2026 | Award | +7,142 | – | – | 12,392 |
| Jean Jacques Bienaime Director | May 15, 2026 | Buy | +1,000 | $10.58 | $10.58K | 9,450 |
| Jean Jacques Bienaime Director | Apr 15, 2026 | Buy | +1,000 | $11.70 | $11.70K | 8,450 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Apr 2, 2026 | Option exercise | +55,000 | $0.30 | $16.50K | 440,708 |
| Jean Jacques Bienaime Director | Mar 9, 2026 | Buy | +2,000 | $11.21 | $22.42K | 7,450 |
| Charles W. Newton Director | Mar 9, 2026 | Award | +13,215 | – | – | 13,215 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Feb 19, 2026 | Sale | −7,015 | $16.17 | $113.43K | 385,708 |
| Esther Cho SVP, General Counsel | Feb 18, 2026 | Sale | −4,745 | $16.35 | $77.58K | 39,755 |
| Lorena Raquel Lerner Chief Science Officer | Feb 18, 2026 | Sale | −3,873 | $16.35 | $63.32K | 31,127 |
| Keith Regnante CHIEF FINANCIAL OFFICER | Feb 18, 2026 | Sale | −4,739 | $16.35 | $77.48K | 39,261 |
| Carl L. Gordon Director | Nov 21, 2025 | Returned to company | −140,057 | $17.75 | $2.49M | 759,155 |
| Carl L. Gordon Director | Nov 21, 2025 | Returned to company | −74,465 | $17.75 | $1.32M | 45,057 |
| Genesis GP LLC OrbiMed Director | Nov 21, 2025 | Returned to company | −74,465 | $17.75 | $1.32M | 45,057 |
| Genesis GP LLC OrbiMed Director | Nov 21, 2025 | Returned to company | −140,057 | $17.75 | $2.49M | 759,155 |
| Julius Knowles Director | Nov 21, 2025 | Returned to company | −130,494 | $17.75 | $2.32M | 102,233 |
| Julius Knowles Director | Nov 21, 2025 | Returned to company | −191,527 | $17.75 | $3.40M | 150,047 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −1,121,045 | $17.75 | $19.90M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −1,226,412 | $17.75 | $21.77M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −155,262 | $17.75 | $2.76M | 0 |
| (China) IV L.P. Pontifax 10% owner | Oct 15, 2025 | Sale | −2,284,612 | $17.75 | $40.55M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −743,358 | $17.75 | $13.19M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −4,391,237 | $17.75 | $77.94M | 0 |
| Daniel Schneeberger 10% owner | Oct 15, 2025 | Sale | −254,669 | $17.75 | $4.52M | 0 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Sep 3, 2025 | Award | +90,500 | – | – | 392,723 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −200 | $70.00 | $14.00K | 743,358 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −100 | $60.00 | $6.00K | 4,392,637 |
| Daniel Schneeberger 10% owner | Jun 20, 2025 | Option exercise | −1,400 | $70.00 | $98.00K | 4,391,237 |
| Alpna Seth Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Carl L. Gordon Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Mary Ann Gray Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Jean Jacques Bienaime Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,450 |
| Ran Nussbaum Director, 10% owner | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Tomer Kariv Director, 10% owner | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| Julius Knowles Director | Jun 4, 2025 | Award | +5,250 | – | – | 6,441 |
| Nima Farzan Director | Jun 4, 2025 | Award | +5,250 | – | – | 5,250 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +74,333 | $10.33 | $767.86K | 4,392,737 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +18,560 | $9.40 | $174.46K | 3,493,404 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +16,365 | $9.40 | $153.83K | 743,558 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +325,000 | $9.86 | $3.20M | 3,818,404 |
| ADAR1 Partners, LP 10% owner | Apr 9, 2025 | Buy | +500,000 | $10.33 | $5.17M | 4,318,404 |
| Jasbir Seehra CHIEF EXECUTIVE OFFICER, Director | Apr 4, 2025 | Option exercise | +49,367 | $0.30 | $14.81K | 302,223 |
| Keith Regnante CHIEF FINANCIAL OFFICER | Feb 18, 2025 | Award | +44,000 | – | – | 44,000 |
| Yung H. Chyung Chief Medical Officer | Feb 18, 2025 | Award | +44,000 | – | – | 44,000 |
| Christopher Rovaldi Chief Operating Officer | Feb 18, 2025 | Award | +60,000 | – | – | 60,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Charles W. Newton Director | Aug 18, 2026 | 551 | $5.72K | Aug 18, 2026 | RSU |
| Charles W. Newton Director | Jun 11, 2026 | 550 | $5.47K | Jun 11, 2026 | RSU |
| Alpna Seth Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| Julius Knowles Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| Nima Farzan Director | Jun 4, 2026 | 2,625 | $28.04K | Jun 4, 2026 | Restricted Stock Unit |
| OrbiMed Genesis Master Fund, LP Shareholder, Director | Mar 31, 2026 | 45,057 | $497.43K | Mar 31, 2026 | IPO |
| Christopher Rovaldi Affiliate | Sep 12, 2025 | 85,306 | $1.34M | Sep 12, 2025 | Exercise of Stock Options |
| OrbiMed Genesis Master Fund, LP Shareholder, Director | Aug 13, 2024 | 29,400 | $1.32M | Aug 13, 2024 | IPO |
| OrbiMed Private Investments VII, LP Shareholder, Director | Aug 13, 2024 | 220,600 | $9.89M | Aug 13, 2024 | IPO |
| Keith Regnante Officer | Jan 4, 2024 | 40,000 | $1.81M | Jan 4, 2024 | Exercise of stock options |
| Biotech Growth Trust PLC The Shareholder | Dec 11, 2023 | 246,000 | $8.77M | Dec 11, 2023 | Private placement |
| Biotech Growth Trust PLC The Shareholder | Jun 12, 2023 | 170,000 | $7.46M | Jun 12, 2023 | Private placement |
| Keith Regnante Officer | Jun 9, 2023 | 20,000 | $908.32K | Jun 9, 2023 | Exercise of Stock Option |
| Keith Regnante Officer | Jun 8, 2023 | 20,000 | $955.85K | Jun 8, 2023 | Exercise of stock options |